|
Sub-category:
Quality-of-Life Management
Category:
Patient Care
Meeting:
2008 ASCO Annual Meeting
Abstract No:
9516
Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 9516)
Author(s):
C. Quinten, C. Coens, M. Mauer, S. Comte, M. Sprangers, C. S. Cleeland, D. Osoba, K. Bjordal, A. Bottomley
Abstract:
Background: While individual studies have suggested baseline QOL (Quality of Life) to be prognostic, results have been contradictory and very few large sample size pooled analyses have been undertaken which could confirm the prognostic value of QOL. Our study aimed to examine if QOL, as assessed by one standardized measure, can predict survival when pooled across a large sample of patients with different disease sites. Such information will provide a rationale to stratify for QOL factors in future clinical trials. Methods: A total of 30 European Organization for Research and Treatment of Cancer (EORTC) Randomized Controlled Trials (RCT) were selected for inclusion in our study, where patients had completed a baseline QOL assessment using the EORTC QLQ-C30 and with survival data. HRQOL parameters were evaluated on a set of 15 standard scales. Clinical data included age (<60 vs >60), gender, distant metastasis, World Health Organization (WHO) performance status (WHO 0-1 vs WHO 2-3) and site were included. Prognostic significance was assessed using Cox proportional hazard models. Bootstrap re-sampling was applied to check the stability of the models. Results: In the pooled analysis, seven QOL endpoints were prognostic; physical functioning (HR=0.992; p<.0001), emotional functioning (HR=1.002; p<0.0142), global health status (HR=0.994; p<.0001), dyspnoea (HR=1.006; p=<.0001), appetite loss (HR=1.007; p=0.0001), constipation (HR=1.002; p=0.0001) and financial difficulties (HR=0.997; p=<.0001). When the analysis was adjusted for clinical variables, physical functioning (HR=0.994; p<.0001), cognitive functioning (HR=1.003; p=0.0105), global health status (HR=0.996; p=0.0006), fatigue (HR=0.997; p=0.0160), nausea and vomiting (HR=1.005; p=0.0004), pain (HR=1.003; p=0.0003), dyspnoea (HR=1.006; p<.0001), and appetite loss (HR=1.005; p<.0001) were prognostic. Conclusions: Our results indicate QOL data are prognostic, and our large sample of patients from RCT gives confidence to the results. Whilst these findings vary by disease site, generally QOL data can help add insight to predicting survival in cancer patients.
Abstract Disclosures
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by C. Quinten :
Presentations by C. Quinten :
Educational Book Manuscripts by C. Quinten :
|
